Encapsulation of poorly soluble drugs in polymer-drug conjugates

Effect of dual-drug nanoformulations on cancer therapy

Thulani H. Senanayake, Yaman Lu, Anna Bohling, Srikumar Raja, Hamid Band, Serguei V. Vinogradov

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Current cancer chemotherapy is gradually shifting to the application of drug combinations that prevent development of drug resistance. Many anticancer drugs have poor solubility and limited oral bioavailability. Using an innovative approach, we developed dual-drug nanoformulations of a polymeric nanogel conjugate with anticancer 5-FU nucleoside analog, floxuridine (FLOX), and the second anticancer drugs, paclitaxel (PCL), or a geldanamycin analog, 17-AAG, for combination therapy. Methods: PCL or 17-AAG had been encapsulated in the cholesteryl-polyvinyl alcohol-floxuridine nanogel (CPVA-FLOX) by simple solution mixing and sonication. Dual nanodrugs formed particles with diameter 180 nm and either drug content (5-20%) that were stable and could be administered orally. Their cytotoxicity in human and mouse cancer cells was determined by MTT assay, and cellular target inhibition - by Western blot analysis. Tumor growth inhibition was evaluated using an orthotopic mouse mammary 4T1 cancer model. Results: CPVA-FLOX was more potent than free drug in cancer models including drug-resistant ones; while dual nanodrugs demonstrated a significant synergy (CPVA-FLOX/PCL), or showed no significant synergy (CPVA-FLOX/17-AAG) compared to free drugs (PCL or 17-AAG). Dual nanodrug CPVA-FLOX/17-AAG effect on its cellular target (HSP70) was similar to 17-AAG alone. In animal model, however, both dual nanodrugs effectively inhibited tumor growth compared to CPVA-FLOX after oral administration. Conclusion: Oral dual-drug nanoformulations of poorly-soluble drugs proved to be a highly efficient combination anticancer therapy in preclinical studies.

Original languageEnglish (US)
Pages (from-to)1605-1615
Number of pages11
JournalPharmaceutical Research
Volume31
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

tanespimycin
Floxuridine
Encapsulation
Polyvinyl Alcohol
Polymers
Pharmaceutical Preparations
Paclitaxel
Neoplasms
Therapeutics
Tumors
Sonication
Chemotherapy
Drug Combinations
Growth
NanoGel
Nucleosides
Drug Resistance
Fluorouracil
Cytotoxicity
Solubility

Keywords

  • 17-AAG
  • dual-drug nanoformulations
  • floxuridine
  • oral delivery
  • paclitaxel

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Encapsulation of poorly soluble drugs in polymer-drug conjugates : Effect of dual-drug nanoformulations on cancer therapy. / Senanayake, Thulani H.; Lu, Yaman; Bohling, Anna; Raja, Srikumar; Band, Hamid; Vinogradov, Serguei V.

In: Pharmaceutical Research, Vol. 31, No. 6, 01.01.2014, p. 1605-1615.

Research output: Contribution to journalArticle

Senanayake, Thulani H. ; Lu, Yaman ; Bohling, Anna ; Raja, Srikumar ; Band, Hamid ; Vinogradov, Serguei V. / Encapsulation of poorly soluble drugs in polymer-drug conjugates : Effect of dual-drug nanoformulations on cancer therapy. In: Pharmaceutical Research. 2014 ; Vol. 31, No. 6. pp. 1605-1615.
@article{4b3ec00f762c4e3bbf45d1d3e5ba8902,
title = "Encapsulation of poorly soluble drugs in polymer-drug conjugates: Effect of dual-drug nanoformulations on cancer therapy",
abstract = "Purpose: Current cancer chemotherapy is gradually shifting to the application of drug combinations that prevent development of drug resistance. Many anticancer drugs have poor solubility and limited oral bioavailability. Using an innovative approach, we developed dual-drug nanoformulations of a polymeric nanogel conjugate with anticancer 5-FU nucleoside analog, floxuridine (FLOX), and the second anticancer drugs, paclitaxel (PCL), or a geldanamycin analog, 17-AAG, for combination therapy. Methods: PCL or 17-AAG had been encapsulated in the cholesteryl-polyvinyl alcohol-floxuridine nanogel (CPVA-FLOX) by simple solution mixing and sonication. Dual nanodrugs formed particles with diameter 180 nm and either drug content (5-20{\%}) that were stable and could be administered orally. Their cytotoxicity in human and mouse cancer cells was determined by MTT assay, and cellular target inhibition - by Western blot analysis. Tumor growth inhibition was evaluated using an orthotopic mouse mammary 4T1 cancer model. Results: CPVA-FLOX was more potent than free drug in cancer models including drug-resistant ones; while dual nanodrugs demonstrated a significant synergy (CPVA-FLOX/PCL), or showed no significant synergy (CPVA-FLOX/17-AAG) compared to free drugs (PCL or 17-AAG). Dual nanodrug CPVA-FLOX/17-AAG effect on its cellular target (HSP70) was similar to 17-AAG alone. In animal model, however, both dual nanodrugs effectively inhibited tumor growth compared to CPVA-FLOX after oral administration. Conclusion: Oral dual-drug nanoformulations of poorly-soluble drugs proved to be a highly efficient combination anticancer therapy in preclinical studies.",
keywords = "17-AAG, dual-drug nanoformulations, floxuridine, oral delivery, paclitaxel",
author = "Senanayake, {Thulani H.} and Yaman Lu and Anna Bohling and Srikumar Raja and Hamid Band and Vinogradov, {Serguei V.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11095-013-1265-3",
language = "English (US)",
volume = "31",
pages = "1605--1615",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Encapsulation of poorly soluble drugs in polymer-drug conjugates

T2 - Effect of dual-drug nanoformulations on cancer therapy

AU - Senanayake, Thulani H.

AU - Lu, Yaman

AU - Bohling, Anna

AU - Raja, Srikumar

AU - Band, Hamid

AU - Vinogradov, Serguei V.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: Current cancer chemotherapy is gradually shifting to the application of drug combinations that prevent development of drug resistance. Many anticancer drugs have poor solubility and limited oral bioavailability. Using an innovative approach, we developed dual-drug nanoformulations of a polymeric nanogel conjugate with anticancer 5-FU nucleoside analog, floxuridine (FLOX), and the second anticancer drugs, paclitaxel (PCL), or a geldanamycin analog, 17-AAG, for combination therapy. Methods: PCL or 17-AAG had been encapsulated in the cholesteryl-polyvinyl alcohol-floxuridine nanogel (CPVA-FLOX) by simple solution mixing and sonication. Dual nanodrugs formed particles with diameter 180 nm and either drug content (5-20%) that were stable and could be administered orally. Their cytotoxicity in human and mouse cancer cells was determined by MTT assay, and cellular target inhibition - by Western blot analysis. Tumor growth inhibition was evaluated using an orthotopic mouse mammary 4T1 cancer model. Results: CPVA-FLOX was more potent than free drug in cancer models including drug-resistant ones; while dual nanodrugs demonstrated a significant synergy (CPVA-FLOX/PCL), or showed no significant synergy (CPVA-FLOX/17-AAG) compared to free drugs (PCL or 17-AAG). Dual nanodrug CPVA-FLOX/17-AAG effect on its cellular target (HSP70) was similar to 17-AAG alone. In animal model, however, both dual nanodrugs effectively inhibited tumor growth compared to CPVA-FLOX after oral administration. Conclusion: Oral dual-drug nanoformulations of poorly-soluble drugs proved to be a highly efficient combination anticancer therapy in preclinical studies.

AB - Purpose: Current cancer chemotherapy is gradually shifting to the application of drug combinations that prevent development of drug resistance. Many anticancer drugs have poor solubility and limited oral bioavailability. Using an innovative approach, we developed dual-drug nanoformulations of a polymeric nanogel conjugate with anticancer 5-FU nucleoside analog, floxuridine (FLOX), and the second anticancer drugs, paclitaxel (PCL), or a geldanamycin analog, 17-AAG, for combination therapy. Methods: PCL or 17-AAG had been encapsulated in the cholesteryl-polyvinyl alcohol-floxuridine nanogel (CPVA-FLOX) by simple solution mixing and sonication. Dual nanodrugs formed particles with diameter 180 nm and either drug content (5-20%) that were stable and could be administered orally. Their cytotoxicity in human and mouse cancer cells was determined by MTT assay, and cellular target inhibition - by Western blot analysis. Tumor growth inhibition was evaluated using an orthotopic mouse mammary 4T1 cancer model. Results: CPVA-FLOX was more potent than free drug in cancer models including drug-resistant ones; while dual nanodrugs demonstrated a significant synergy (CPVA-FLOX/PCL), or showed no significant synergy (CPVA-FLOX/17-AAG) compared to free drugs (PCL or 17-AAG). Dual nanodrug CPVA-FLOX/17-AAG effect on its cellular target (HSP70) was similar to 17-AAG alone. In animal model, however, both dual nanodrugs effectively inhibited tumor growth compared to CPVA-FLOX after oral administration. Conclusion: Oral dual-drug nanoformulations of poorly-soluble drugs proved to be a highly efficient combination anticancer therapy in preclinical studies.

KW - 17-AAG

KW - dual-drug nanoformulations

KW - floxuridine

KW - oral delivery

KW - paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=84902175055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902175055&partnerID=8YFLogxK

U2 - 10.1007/s11095-013-1265-3

DO - 10.1007/s11095-013-1265-3

M3 - Article

VL - 31

SP - 1605

EP - 1615

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 6

ER -